摘要
lurbinectedin是一种RNA聚合酶Ⅱ抑制剂,可抑制肿瘤相关巨噬细胞的致癌基因转录,属于注射用烷基化药物,可用于治疗铂类化疗治疗中或治疗后疾病进展的小细胞肺癌(SCLC)成年患者。本品常见的不良反应有可逆性骨髓抑制和肝毒性。本文对其药理学、临床评价、药物相互作用、安全性、药动学及用法用量进行综述。
Lurbinectedin is an RNA polymerase Ⅱ inhibitor that inhibits oncogene transcription in tumor-associated macrophages. It belongs to an injectable alkylated drug that can be used for the treatment of small cell lung cancer(SCLC) in adult patients with disease progression during or after platinum chemotherapy. The common adverse reactions include reversible myelosuppression and liver toxicity. This review summarizes pharmacology, clinical evaluation, drug interaction, safety, pharmacokinetics and dosage regarding this drug.
作者
蓝花
张亚同
王洋
LAN Hua;ZHANG Ya-tong;WANG Yang(Department of Pharmacy,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing100730,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2021年第21期1934-1939,共6页
Chinese Journal of New Drugs
